Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel drug delivery platform for oral delivery of large molecule protein active pharmaceutical ingredients.

Entera Bio is currently conducting clinical trials of three candidate drugs based on applying Entera's technology to teriparatide for the treatment of hypoparathyroidism, osteoporosis, and bone healing

Entera Bio is managed by a knowledgeable and experienced management team with more than 50 years of experience in drug development.